soul trial oral semaglutide cardiovascular outcomes results 2024 nejm and in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the Randomized Trial Scorecard: SOUL

Those with hepatic impairment, thyroid cancer risk, pancreatitis history, or uncontrolled diabetes may require branded alternatives with expanded clinical data

The service provided has been exceptional

In rare instances, or special circumstances a compounded version of the medication may be offered, if clinically indicated

Yki-Jrvinen H

Common semaglutide side effects include nausea, vomiting, and diarrhea which typically subside within a few weeks of the initial treatment

Eighteen percent of patients had BRAF V600 pathogenic variants, 39% had an elevated lactate dehydrogenase (LDH) level, 64% had M1c disease, 9% had brain metastases, and 72% had undergone two or more therapies for advanced disease